Traders should monitor for topline results from PALISADE-4 expected within Q2 2026. A positive outcome could be a significant catalyst for the stock given the $23M market cap; a negative result would likely be bearish.
Price Chart
Executive Summary
Vistagen announced the completion of the last patient visit in the randomized portion of its PALISADE-4 Phase 3 trial evaluating fasedienol nasal spray for social anxiety disorder. Topline results are expected in the second quarter of 2026. This is a routine clinical milestone with no financial data disclosed.
Key Facts
- Last patient completed last visit in randomized portion of PALISADE-4 Phase 3 trial.
- Topline results expected in Q2 2026.
- Open label extension (OLE) portion remains ongoing.
- FDA Fast Track designation for fasedienol in social anxiety disorder.
- Statistical analysis plan (SAP) refined to incorporate pre-IP SUDS as covariate; FDA had no comments.
Financial Impact
No financial data disclosed in the filing.
Risk Factors
- No guarantee of positive trial outcome despite SAP refinements.
- Previous PALISADE trials (1 and 3) have not been reported as positive.
- Stock may be volatile around topline data release.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-032935 |
| Document: pal-4lplvprex991.htm | 0001628280-26-032935 |
| Document: 0001628280-26-032935-index-headers.html | 0001628280-26-032935 |
| Document: 0001628280-26-032935-index.html | 0001628280-26-032935 |
| Document: 0001628280-26-032935.txt | 0001628280-26-032935 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $0.2676 $0.2432 | ▲ +9.12% | ▲ +7.13% | $0.2847 (−6.39%) |
Aug 14, 2026 7w ago | Press Release | $0.2676 $0.2432 | ▼ −9.12% | ▼ −7.13% | $0.2847 (+6.39%) |
Jul 31, 2026 9w ago | 8-K | $0.2410 $0.2529 | ▲ +4.94% | ▲ +1.95% | $0.2847 (+18.13%) |
Jun 30, 2026 13w ago | 8-K | $0.2260 $0.2302 | ▼ −1.86% | ▼ −2.89% | $0.2847 (−25.97%) |
Jun 17, 2026 15w ago | 8-K | $0.6702 $0.2400 | ▼ −64.19% | ▼ −64.72% | $0.2847 (−57.52%) |
Jun 15, 2026 15w ago | 8-K | $0.6900 $0.2461 | ▼ −64.33% | ▼ −64.53% | $0.2847 (−58.74%) |
Jun 11, 2026 16w ago | Institutional Cluster | $0.5731 $0.2492 | ▼ −56.52% | ▼ −58.41% | $0.2847 (−50.32%) |
Jun 9, 2026 16w ago | 8-K | $0.5351 $0.2492 | ▼ −53.43% | ▼ −57.05% | $0.2847 (−46.79%) |
May 19, 2026 19w ago | 8-K | $0.6400 $0.6702 | ▲ +4.72% | ▲ +3.98% | $0.2847 (−55.52%) |
May 12, 2026 20w ago | 8-K | $0.6200 $0.5400 | ▼ −12.90% | ▼ −11.18% | $0.2847 (−54.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access